Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease (Q45259878)

11 December 2017

Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease (English)

1 reference

11 December 2017

0 references

0 references

12

1 reference

11 December 2017

Françoise Imbert-Bismut

5

object named as

Françoise Imbert-Bismut

0 references

Mona Munteanu

10

object named as

Mona Munteanu

1 reference

11 December 2017

3

Vlad Ratziu

1 reference

11 December 2017

6

Djamila Messous

1 reference

11 December 2017

9

Dominique Thabut

1 reference

11 December 2017

1

Sylvie Naveau

1 reference

11 December 2017

4

Annie Abella

1 reference

11 December 2017

Bruno Raynard

2

1 reference

11 December 2017

Françoise Imbert-Bismut

5

1 reference

11 December 2017

Fabienne Beuzen

7

1 reference

11 December 2017

Frédérique Capron

8

1 reference

11 December 2017

Jean Claude Chaput

11

1 reference

11 December 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

Clinical Gastroenterology and Hepatology

11 December 2017

1 reference

11 December 2017

3

1 reference

11 December 2017

2

1 reference

11 December 2017

167-174

1 reference

Advances in alcoholic liver disease

11 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Liver disease in alcohol abusers: clinical perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Detection of alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Alcoholic liver disease (ALD): a new domain for prevention efforts

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Mortality and life-years lost due to alcohol: a comparison of acute and chronic causes

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Pathogenesis, diagnosis, and treatment of alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

A 21-year experience with major hemorrhage after percutaneous liver biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Appropriateness of liver biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF).

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Noninvasive diagnosis of hepatic fibrosis or cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Alpha-2-macroglobulin and hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

A comparison of four serum markers of fibrosis in the diagnosis of cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Serum markers for hepatic fibrosis in alcoholic liver disease: which is the best marker, type III procollagen, type IV collagen, laminin, tissue inhibitor of metalloproteinase, or prolyl hydroxylase?

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest)

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Excess weight risk factor for alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Observer Variation in Assessment of Liver Biopsies of Alcoholic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

A comparison of fibrosis progression in chronic liver diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

A method of comparing the areas under receiver operating characteristic curves derived from the same cases

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Apolipoprotein AI and alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Apolipoprotein AI is a serum and tissue marker of liver fibrosis in alcoholic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Review article: Nutritional therapy in alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

Sampling variability of liver fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900625-1

1 reference

7 January 2021

10.1016/S1542-3565(04)00625-1

Identifiers

DOI

1 reference

11 December 2017

1 reference